Daily Sabah logo

Politics
Diplomacy Legislation War On Terror EU Affairs Elections News Analysis
TÜRKİYE
Istanbul Education Investigations Minorities Expat Corner Diaspora
World
Mid-East Europe Americas Asia Pacific Africa Syrian Crisis Islamophobia
Business
Automotive Economy Energy Finance Tourism Tech Defense Transportation News Analysis
Lifestyle
Health Environment Travel Food Fashion Science Religion History Feature Expat Corner
Arts
Cinema Music Events Portrait Reviews Performing Arts
Sports
Football Basketball Motorsports Tennis
Opinion
Columns Op-Ed Reader's Corner Editorial
PHOTO GALLERY
JOBS ABOUT US RSS PRIVACY CONTACT US
© Turkuvaz Haberleşme ve Yayıncılık 2023

Daily Sabah logo

عربي
  • Politics
    • Diplomacy
    • Legislation
    • War On Terror
    • EU Affairs
    • Elections
    • News Analysis
  • TÜRKİYE
    • Istanbul
    • Education
    • Investigations
    • Minorities
    • Expat Corner
    • Diaspora
  • World
    • Mid-East
    • Europe
    • Americas
    • Asia Pacific
    • Africa
    • Syrian Crisis
    • Islamophobia
  • Business
    • Automotive
    • Economy
    • Energy
    • Finance
    • Tourism
    • Tech
    • Defense
    • Transportation
    • News Analysis
  • Lifestyle
    • Health
    • Environment
    • Travel
    • Food
    • Fashion
    • Science
    • Religion
    • History
    • Feature
    • Expat Corner
  • Arts
    • Cinema
    • Music
    • Events
    • Portrait
    • Reviews
    • Performing Arts
  • Sports
    • Football
    • Basketball
    • Motorsports
    • Tennis
  • Gallery
  • Opinion
    • Columns
    • Op-Ed
    • Reader's Corner
    • Editorial
  • TV
  • Life
  • Health
  • Environment
  • Travel
  • Food
  • Fashion
  • Science
  • Religion
  • History
  • Feature
  • Expat Corner

Immunocompromised to benefit from new coronavirus jab under trial

by French Press Agency - AFP

Paris Nov 23, 2021 - 8:56 pm GMT+3
A medical worker prepares a syringe with a vaccine against COVID-19 in Frankfurt am Main, Nov. 23, 2021. (AFP Photo)
A medical worker prepares a syringe with a vaccine against COVID-19 in Frankfurt am Main, Nov. 23, 2021. (AFP Photo)
by French Press Agency - AFP Nov 23, 2021 8:56 pm
RECOMMENDED
Manufacturers appear to be taking advantage of people's vitamin B12 need with misleading packaging. (dpa Photo)

'Extra strength'? Misleading packaging of vitamin B12 supplements

VITAMINS

A coronavirus vaccine being produced by a German team was shown to generate a strong white blood response in trials, according to results of a research Tuesday. This jab will be especially useful for those with compromised immune systems.

The jab, known as CoVac-1, being developed at Germany's University of Tuebingen, was shown to produce a strong white blood cell – or T-cell – response in all 36 Phase 1 trial participants.

T-cells are white blood cells that attack and neutralize whole infected cells. This is unlike an antibody response, provoked by traditional COVID-19 and other vaccines, which targets specific pathogens within the body directly.

This secondary immune response is potentially vital for patients with suppressed immune systems for whom existing COVID-19 vaccines on the market offer weaker levels of protection against severe disease.

Transplant recipients, for example, receive treatment to stifle antibody activity to prevent their bodies from rejecting the life-saving organ.

For them and others such as cancer patients, bypassing the antibody response and targeting T-cells may prove the best way to mount an immune response to COVID-19.

Participants in the trial were between 18 and 80 years old and received a single dose of the vaccine.

"CoVac-1 showed a favourable safety profile and induced broad, potent... T-cell responses," the study said, noting that the results were the same when tested against COVID-19 variants.

The team reported that the strength of the T-cell response provoked by the jab was stronger than that which has been observed through infection with COVID-19.

The effects of the jab were seen to last up to three months, according to the research published in Nature.

The report said the very preliminary results support the already ongoing Phase 2 trials being conducted in patients with immunodeficiencies.

Phase 2 trials typically contain larger cohorts than Phase 1 and will likely provide important data on the vaccine's efficacy and safety for all types of patients.

"CoVac-1 may well serve as a (complementary) vaccine ... particularly in elderly and immunocompromised individuals with impaired ability to mount sufficient immune responses after SARS-CoV-2 vaccination with currently approved vaccines," it added.

RECOMMENDED
Manufacturers appear to be taking advantage of people's vitamin B12 need with misleading packaging. (dpa Photo)

'Extra strength'? Misleading packaging of vitamin B12 supplements

VITAMINS
  • shortlink copied
  • RELATED TOPICS
    fight-against-terrorism DEUTSCHE-BANK US-LIBYA-RELATIONS
    KEYWORDS
    coronavirus vaccine
    The Daily Sabah Newsletter
    Keep up to date with what’s happening in Turkey, it’s region and the world.
    You can unsubscribe at any time. By signing up you are agreeing to our Terms of Use and Privacy Policy. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
    A Turkish police officer stands guard in front of the closed Dutch Consulate in Istanbul, Türkiye, Feb. 1, 2023. (Reuters Photo)

    Türkiye angered over 'intentional' closure of foreign missions

    türkiye-eu-relations
    A Kangal dog and a lamb are seen in Elazığ, eastern Türkiye, Feb. 3, 2023. (IHA Photo)

    Turkish Kangal dog embraces role of mother to lamb

    KANGAL-DOG

    Over 200 flights cancelled in Istanbul due to expected snowstorm

    snowstorm

    'All of Ukraine will burn' due to US supplies: Russia's Medvedev

    Russian-invasion-of-Ukraine
    No Image
    Schools shut, work from home in Delhi as India smothered by smog
    PHOTOGALLERY
    • POLITICS
    • Diplomacy
    • Legislation
    • War On Terror
    • EU Affairs
    • News Analysis
    • TÜRKİYE
    • Istanbul
    • Education
    • Investigations
    • Minorities
    • Diaspora
    • World
    • Mid-East
    • Europe
    • Americas
    • Asia Pacific
    • Africa
    • Syrian Crisis
    • İslamophobia
    • Business
    • Automotive
    • Economy
    • Energy
    • Finance
    • Tourism
    • Tech
    • Defense
    • Transportation
    • News Analysis
    • Lifestyle
    • Health
    • Environment
    • Travel
    • Food
    • Fashion
    • Science
    • Religion
    • History
    • Feature
    • Expat Corner
    • Arts
    • Cinema
    • Music
    • Events
    • Portrait
    • Performing Arts
    • Reviews
    • Sports
    • Football
    • Basketball
    • Motorsports
    • Tennis
    • Opinion
    • Columns
    • Op-Ed
    • Reader's Corner
    • Editorial
    • Photo gallery
    • Jobs
    • privacy
    • about us
    • contact us
    • RSS
    © Turkuvaz Haberleşme ve Yayıncılık 2021